Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29167283 | 1.00 | CYP1A2 (0.39) | CYP1A2LMNACYP2D6SRCTSHR | |
| SCHEMBL10884348 | 0.78 | ESR1 (0.40) | — | |
| SCHEMBL5152961 | 0.76 | CYP1A2 (0.45) | CYP1A2LMNACYP2D6SRCTSHR | |
| SCHEMBL27690229 | 0.76 | MMP8 (0.43) | CYP1A2LMNACYP2D6TSHRL3MBTL1 | |
| SCHEMBL29141154 | 0.73 | CYP1A2 (0.42) | CYP1A2LMNACYP2D6SRCTSHR | |
| SCHEMBL10690917 | 0.73 | CYP1A2 (0.42) | CYP1A2LMNACYP2D6SRCTSHR | |
| SCHEMBL8525796 | 0.70 | TSHR (0.55) | LMNACYP2D6SRCTSHRMAPK1 | |
| SCHEMBL9435845 | 0.69 | TSHR (0.38) | CYP1A2LMNACYP2D6SRCTSHR | |
| SCHEMBL6533418 | 0.68 | CYP2C19 (0.44) | CYP1A2LMNACYP2D6SRCTSHR | |
| SCHEMBL11616150 | 0.67 | LMNA (0.38) | CYP1A2LMNACYP2D6SRCTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117625666-A | Construction method and application of pasteurella multocida resistance marker gene-free integrated strain | 华南农业大学 | 2024-03-01 | — | — | CN | claimed |
| EP-3149029-B1 | LIPIDATED PEPTIDES AS NEUROPROTECTIVE AGENTS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2019-06-19 | — | — | EP | claimed |
| EP-3094643-B1 | LIPIDATED PEPTIDES FOR LOWERING BLOOD GLUCOSE | FYZIOLOGICKY USTAV AKADEMIE VED CESKE REPUBLIKY V V I (CZ) | 2018-10-17 | — | — | EP | claimed |
| EP-3149029-A1 | LIPIDATED PEPTIDES AS NEUROPROTECTIVE AGENTS | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. (CZ) | 2017-04-05 | — | — | EP | claimed |
| US-20170051031-A1 | LIPIDATED PEPTIDES AS NEUROPROTECTIVE AGENTS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2017-02-23 | — | — | US | claimed |
| WO-2015180698-A1 | LIPIDATED PEPTIDES AS NEUROPROTECTIVE AGENTS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2015-12-03 | — | — | WO | claimed |
| CN-117625666-A | Construction method and application of pasteurella multocida resistance marker gene-free integrated strain | 华南农业大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-117625666-A | Construction method and application of pasteurella multocida resistance marker gene-free integrated strain | 华南农业大学 | 2024-03-01 | — | — | CN | disclosed |
| US-10751390-B2 | Lipidated peptides as neuroprotective agents | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2020-08-25 | — | — | US | disclosed |
| EP-3149029-B1 | LIPIDATED PEPTIDES AS NEUROPROTECTIVE AGENTS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2019-06-19 | — | — | EP | disclosed |
| US-20170051031-A1 | LIPIDATED PEPTIDES AS NEUROPROTECTIVE AGENTS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10751390-B2 | Lipidated peptides as neuroprotective agents | GABARAPL1, GABARAP, GABARAPL2 | CYP1A2 4849/4885LMNA 3447/4885CYP2D6 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.